Comments
The S&P 500 lost ground on Tuesday as concerns over a new variant of the coronavirus and disappointing economic data stole the thunder from Washington'spassage of a long-awaited pandemic relief bill.
The Dow also closed lower, while Apple Inc helped push the tech-heavy Nasdaq's to an all-time closing high.
The Dow Jones Industrial Average fell 200.94 points,or 0.67%, to 30,015.51, the S&P 500 lost 7.66 points, or0.21%, to 3,687.26 and the Nasdaq Composite added 65.40 points, or 0.51%, to 12,807.92.
Of the 11 major sectors in the S&P 500, only tech and real estate ended the session in positive territory.
Small caps advanced, with the Russell 2000 also closing at a record level.
"Today the market is catching its breath," said RyanDetrick, senior market strategist at LPL Financial in Charlotte,North Carolina. "It's digesting the two big pieces of news we've gotten in the last 24 hours, the stimulus and the new Covid strain."
Apple was an outlier amid a broad sell-off, gaining 2.8% and providing the biggest lift to the S&P 500 and the Nasdaq on newsof the company's plans to roll out an electric passenger vehicle by 2024.
Covid-19 relief package
Overnight, Congress passed a pandemic relief package worth $892 billion after months of a partisan tug-of-war, aimed at propping up an economic recovery faltering under the weight of restrictions aimed at containing a coronavirus resurgence.
That resurgence continues to swell, infecting 214,000 Americans every day, prompting mandatory shutdowns and pushing hospitals to capacity.
A fast-spreading new variant of the virus discovered in Britain has brought movement in and out of the UK to a halt and sent vaccine makers Pfizer Inc and Moderna Inc scrambling to ensure their drugs were effective against it.
On the economic front, consumer confidence unexpectedly dropped while sales of pre-owned US homes posted their first decline in six months.
Tesla Inc fell 1.5%, extending its slide on its second day as a S&P 500 constituent.
Peloton Interactive Inc jumped 11.6% as brokers hiked their price targets on the stock on the heels of the company's announcement that it would buy peer Precor in a deal worth $420 million.
Amgen Inc slid 2.8% after disappointing results from a late-stage study of an asthma drug developed in a partnership with British drugmaker AstraZeneca Plc.
Declining issues outnumbered advancing ones on the NYSE by a1.31-to-1 ratio; on Nasdaq, a 1.21-to-1 ratio favored advancers.
The S&P 500 posted 23 new 52-week highs and one new low; the Nasdaq Composite recorded 323 new highs and 11 new lows.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.